Parallels in Sepsis and COVID-19 Conditions: Implications for Managing Severe COVID-19

Front Immunol. 2021 Feb 3:12:602848. doi: 10.3389/fimmu.2021.602848. eCollection 2021.

Abstract

Sepsis is a life-threatening systemic illness attributed to a dysregulated host response to infection. Sepsis is a global burden killing ~11 million persons annually. In December 2019, a novel pneumonia condition termed coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged and has resulted in more than 1,535,982 deaths globally as of 8th December 2020. These two conditions share many pathophysiological and clinical features. Notably, both sepsis and COVID-19 patients experience consumptive thrombocytopenia, haemolytic anaemia, vascular microthrombosis, multi-organ dysfunction syndrome, coagulopathy, septic shock, respiratory failure, fever, leukopenia, hypotension, leukocytosis, high cytokine production and high predisposition to opportunistic infections. Considering the parallels in the immunopathogenesis and pathophysiological manifestations of sepsis and COVID-19, it is highly likely that sepsis care, which has a well-established history in most health systems, could inform on COVID-19 management. In view of this, the present perspective compares the immunopathogenesis and pathophysiology of COVID-19 and non-SARS-CoV-2 induced sepsis, and lessons from sepsis that can be applicable to COVID-19 management.

Keywords: COVID-19; SARS-CoV-2; coronavirus; cytokine storm; hypovolemia; immunosuppression; sepsis.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • COVID-19 / diagnosis*
  • COVID-19 / therapy
  • Cytokine Release Syndrome
  • Humans
  • Hypovolemia
  • Immune Tolerance
  • Respiratory Insufficiency
  • SARS-CoV-2 / physiology*
  • Sepsis / diagnosis*
  • Sepsis / therapy
  • Thrombosis